Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma

Abstract

This trial failed to demonstrate clinical benefit of specific immunotherapy. The subset of vaccinated patients mounting specific anti-Id responses had superior outcomes. Whether this reflects a therapeutic benefit or is a marker for more favorable underlying prognosis requires further study.